Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GNLX Genelux Corp
- Stocks
- Healthcare
- NASDAQ: GNLX
Price (delayed)
$2.48
Market cap
$93.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.88
Enterprise value
$79.16M
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product
Highlights
GNLX's equity has soared by 98% YoY and by 14% from the previous quarter
Genelux's quick ratio has soared by 82% YoY and by 2% from the previous quarter
Genelux's revenue has shrunk by 100% QoQ
GNLX's gross profit has dropped by 100% since the previous quarter
Key stats
What are the main financial stats of GNLX
Market
Valuations
Earnings
Shares outstanding
37.73M
Market cap
$93.58M
Enterprise value
$79.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.88
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$31.4M
Net income
-$29.51M
EBIT
-$29.51M
EBITDA
-$28.55M
Free cash flow
-$22.69M
Per share
Balance sheet
Liquidity
EPS
-$0.88
EPS diluted
-$0.88
Free cash flow per share
-$0.65
Book value per share
$0.86
Revenue per share
$0
TBVPS
$1.12
Total assets
$38.99M
Total liabilities
$9.14M
Debt
$1.79M
Equity
$29.85M
Working capital
$28.26M
Debt to equity
0.06
Current ratio
4.67
Quick ratio
4.57
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-74.2%
Return on equity
-93%
Return on invested capital
-115.3%
Return on capital employed
-94.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GNLX stock price
How has the Genelux stock price performed over time
Intraday
2.48%
1 week
-16.22%
1 month
-3.5%
1 year
-31.11%
YTD
5.08%
QTD
-8.15%
Financial performance
How have Genelux's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.4M
Net income
-$29.51M
Gross margin
N/A
Net margin
N/A
Genelux's revenue has shrunk by 100% QoQ
GNLX's gross profit has dropped by 100% since the previous quarter
The company's operating income fell by 22% YoY
The net income has contracted by 14% YoY
Price vs fundamentals
How does GNLX's price correlate with its fundamentals
Growth
What is Genelux's growth rate over time
Valuation
What is Genelux stock price valuation
P/E
N/A
P/B
2.88
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 9% YoY and by 7% QoQ
GNLX's equity has soared by 98% YoY and by 14% from the previous quarter
GNLX's price to book (P/B) is 15% higher than its last 4 quarters average of 2.5
Genelux's revenue has shrunk by 100% QoQ
Efficiency
How efficient is Genelux business performance
Genelux's return on invested capital has surged by 73% YoY and by 2.9% QoQ
GNLX's ROE is up by 27% YoY and by 13% from the previous quarter
Genelux's return on assets has increased by 15% YoY and by 10% QoQ
Dividends
What is GNLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GNLX.
Financial health
How did Genelux financials performed over time
Genelux's quick ratio has soared by 82% YoY and by 2% from the previous quarter
The current ratio has soared by 72% year-on-year and by 2.2% since the previous quarter
GNLX's debt is 94% smaller than its equity
GNLX's equity has soared by 98% YoY and by 14% from the previous quarter
GNLX's debt to equity has plunged by 63% YoY and by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.